ArticleGynecologic oncology2020
Predictors of survival trajectories among women with epithelial ovarian cancer.
Article in Gynecologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 40 citations in OpenAlex.
- Development and validation of tumor-size-stratified prognostic nomograms for patients with uterine sarcoma: A SEER database analysis.Cancer medicine · 2023Trial
- A Multistate Survival Model to Identify Risk Factors for Lethal Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Manifestations and Influencing Factors of Posttraumatic Growth Among Ovarian Cancer Patients Undergoing Chemotherapy: A Qualitative Exploration.International journal of women's health · 2026Article
- SCENE: Signature Collection for Endometrial Cancer Prognosis.Journal of cellular and molecular medicine · 2025Review
- Development of model for identifying homologous recombination deficiency (HRD) status of ovarian cancer with deep learning on whole slide images.Journal of translational medicine · 2025Article
- The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma.Cancer immunology research · 2024Article
- A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma.NAR genomics and bioinformatics · 2024Article
- Value analysis of preoperative peripheral blood LMR in predicting prognosis of serous papillary ovarian adenocarcinoma.Discover oncology · 2024Article
- Molecular Subtypes of High-Grade Serous Ovarian Cancer across Racial Groups and Gene Expression Platforms.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Association between BMI and oncologic outcomes in epithelial ovarian cancer: a predictors-matched case-control study.Archives of gynecology and obstetrics · 2024Article
- Article
- Molecular subtypes of high-grade serous ovarian cancer across racial groups and gene expression platforms.bioRxiv : the preprint server for biology · 2023Article
- Reevaluating the Role of Progesterone in Ovarian Cancer: Is Progesterone Always Protective?Endocrine reviews · 2023Article
- Dissecting mammalian reproduction with spatial transcriptomics.Human reproduction update · 2023Review
- Article
- Preliminary outcomes of five-year survival for ovarian malignancies in profiled Serbian Oncology Centre.Clinics (Sao Paulo, Brazil) · 2023Article
- Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma.Cancers · 2022Article
- Predictors of early mortality risk in patients with epithelial ovarian cancer.Health science reports · 2022Article
- Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3).International journal of epidemiology · 2022Article
- Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.Gynecologic oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
objectiveAlthough ovarian cancer is a deadly disease, approximately a third of women survive ≥9 years after diagnosis. The factors associated with achieving long-term survival are not well understood. In this study, data from the Surveillance, Epidemiology, and End Results (SEER) program were used to determine predictors of survival trajectories among women with epithelial ovarian cancer and across histotype (high-grade serous carcinoma (HGSC) and non-HGSC).
methodsData on 35,868 women diagnosed with epithelial ovarian cancer in 2004-2016 were extracted from SEER. Extended Cox proportional hazards regression was used to estimate overall and histotype-specific associations between patient and tumor characteristics and all-cause mortality within each survival time (t) interval (t < 3, 3 ≤ t < 6, 6 ≤ t < 9, and 9 ≤ t < 13 years).
resultsAge at diagnosis, marital status, race/ethnicity, stage, and surgery were more strongly associated with mortality in the short-term survival period, and these associations waned with increasing survival time. Exceptions to this pattern were age >70 years at diagnosis, where a high risk of mortality was observed in both the t < 3 and t ≥ 9 year time periods, and non-Hispanic Asian/Pacific Islanders, where a more pronounced inverse association with mortality was observed in t ≥ 9 years after diagnosis. Similar associations were observed for HGSC, although the waning effect was not apparent for most characteristics. Mortality associations for non-HGSC were more pronounced for stage and race/ethnicity, primarily for non-Hispanic Asian/Pacific Islanders.
conclusionsMost patient and tumor characteristics were more strongly associated with mortality in the years following diagnosis, but have declining impact with increasing survival time. Given this waning effect, it is critical to identify factors impacting risk of mortality as ovarian cancer patients advance through the survival trajectory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.